Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.
Glatt S, Baeten D, Baker T, Griffiths M, Ionescu L, Lawson ADG, Maroof A, Oliver R, Popa S, Strimenopoulou F, Vajjah P, Watling MIL, Yeremenko N, Miossec P, Shaw S. Glatt S, et al. Among authors: watling mil. Ann Rheum Dis. 2018 Apr;77(4):523-532. doi: 10.1136/annrheumdis-2017-212127. Epub 2017 Dec 23. Ann Rheum Dis. 2018. PMID: 29275332 Free PMC article. Clinical Trial.
Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study.
Oliver R, Krueger JG, Glatt S, Vajjah P, Mistry C, Page M, Edwards H, Garcet S, Li X, Dizier B, Maroof A, Watling M, El Baghdady A, Baeten D, Ionescu L, Shaw S. Oliver R, et al. Br J Dermatol. 2022 Apr;186(4):652-663. doi: 10.1111/bjd.20827. Epub 2021 Dec 27. Br J Dermatol. 2022. PMID: 34687214 Free PMC article. Clinical Trial.
Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.
Glatt S, Taylor PC, McInnes IB, Schett G, Landewé R, Baeten D, Ionescu L, Strimenopoulou F, Watling MIL, Shaw S. Glatt S, et al. Among authors: watling mil. Ann Rheum Dis. 2019 Aug;78(8):1033-1040. doi: 10.1136/annrheumdis-2018-214943. Epub 2019 Jun 8. Ann Rheum Dis. 2019. PMID: 31177099 Free PMC article. Clinical Trial.
Brief exercise induces an immediate and a delayed leucocytosis.
McCarthy DA, Grant M, Marbut M, Watling M, Wade AJ, Macdonald I, Nicholson S, Melsom RD, Perry JD. McCarthy DA, et al. Br J Sports Med. 1991 Dec;25(4):191-5. doi: 10.1136/bjsm.25.4.191. Br J Sports Med. 1991. PMID: 1810612 Free PMC article.
Blood pressure and exercise testing.
Davies SW, Wannamethee G, Lipkin DP, Emery TM, Watling MI. Davies SW, et al. Lancet. 1991 Aug 31;338(8766):569. doi: 10.1016/0140-6736(91)91129-i. Lancet. 1991. PMID: 1678817 No abstract available.